Transthyretin Amyloid Cardiomyopathy Clinical Trials

44 clinical trials for Transthyretin Amyloid Cardiomyopathy across international registries, including 19 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis — RECRUITING · PHASE3
• A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting — RECRUITING
• A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis — RECRUITING · PHASE4
• (23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis. — RECRUITING · PHASE4
• A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis. — RECRUITING · PHASE1
• A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CONCOMITANT USE OF EPLONTERSEN AND ALXN2220 COMPARED WITH EPLONTERSEN AND PLACEBO IN ADULT PARTICIPANTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) — RECRUITING · PHASE2
• CLEOPATTRA: EFFECTS OF NNC6019-0001 VERSUS PLACEBO ON CARDIOVASCULAR OUTCOMES IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRCM) — RECRUITING
• A PHASE 3, OPEN-LABEL, MULTICENTER, EXTENSION STUDY OF ACORAMIDIS IN PATIENTS WITH NEWLY DIAGNOSED VARIANT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ACTEARLY OLE) — RECRUITING · PHASE3
• Phenotyping and Characterization of wtATTR-CM (TRACE 1) — RECRUITING
• Thailand ATTR-CM Registry — RECRUITING
• FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases — RECRUITING
• Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery — RECRUITING
• MAGNITUDE: A PHASE 3, MULTINATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NTLA-2001 IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR-CM) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMYLOID DEPLETER ALXN2220 IN ADULT PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) — RECRUITING · PHASE3
• AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY OF EPLONTERSEN (ION-682884) IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) — RECRUITING
• EFFICACY ANDD SAFETY OF NNC6019-0001 AT TWO DOSE LEVELS IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM) — RECRUITING
• AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF ACORAMIDIS (AG10) IN PARTICIPANTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY WHO COMPLETED THE PHASE 3 ATTRIBUTE-CM TRIAL (AG10-301) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY) — RECRUITING · PHASE3
• A PHASE 3 GLOBAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION-682884 IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM) — RECRUITING · PHASE3
• Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor — NOT_YET_RECRUITING
• Study of ALXN2220 Versus Placebo in Adults With ATTR-CM — ACTIVE_NOT_RECRUITING · PHASE3
• Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) — NOT_YET_RECRUITING · PHASE4
• A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM — ACTIVE_NOT_RECRUITING · PHASE2
• Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM — NOT_YET_RECRUITING
• EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy — ACTIVE_NOT_RECRUITING · PHASE3
• Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy — COMPLETED · NA
• A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis — COMPLETED · PHASE2
• Cardiac Amyloidosis in Patients With Aortic Stenosis — NOT_YET_RECRUITING
• Bronx Transthyretin Amyloid Cardiomyopathy Database — ACTIVE_NOT_RECRUITING
• A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) — COMPLETED
• A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India — COMPLETED
• carDIo-ttranSSfOrm nucLEar Imaging Study — TERMINATED
• A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) — COMPLETED · PHASE4
• i-Care; Quantitative-imaging in cardiac transthyretin amyloidosis — NOT_YET_RECRUITING · PHASE4
• Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis — COMPLETED · PHASE1
• SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy — COMPLETED · PHASE4
• Global Prevalence of ATTR-CM in Participants With HFpEF — TERMINATED · NA
• Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis — OTHER
• Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction — OTHER · NA
• A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting — OTHER · NA
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRIBUTE-CM TRIAL) — COMPLETED · PHASE3
• A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM) — COMPLETED · PHASE3
• A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM) — COMPLETED · PHASE3

Refine this search